Results 31 to 40 of about 41,114 (313)

Role of cardiac MRI in the diagnosis of cardiac amyloidosis. Clinical cases

Клинический разбор в общей медицине, 2021
Purpose. The aim of this work is to show the capabilities of late gadolinium enhancement cardiac magnetic resonance imaging (MRI) in the diagnosis of a rare disease such as cardiac amyloidosis. Materials and methods.
Ekaterina A. Butorova , Olga V. Stukalova   +1 more
doaj   +1 more source

Tensorial tomographic Fourier Ptychography with applications to muscle tissue imaging [PDF]

Tensorial tomographic Fourier Ptychography with applications to muscle tissue imaging, Adv. Photon. 6(2), 026004 (2024), 2023
We report Tensorial tomographic Fourier Ptychography (ToFu), a new non-scanning label-free tomographic microscopy method for simultaneous imaging of quantitative phase and anisotropic specimen information in 3D. Built upon Fourier Ptychography, a quantitative phase imaging technique, ToFu additionally highlights the vectorial nature of light.
arxiv   +1 more source

Utility and pitfalls of the electrocardiogram in the evaluation of cardiac amyloidosis

Annals of Noninvasive Electrocardiology, 2022
Background Cardiac amyloidosis is a protein misfolding disorder involving deposition of amyloid fibril proteins in the heart. The associated fibrosis of the conduction tissue results in conduction abnormalities and arrhythmias.
Perryn Lin Fei Ng, Yoke Ching Lim, Lauren Kay Mance Evangelista, Raymond Ching Chiew Wong, Ping Chai, Ching Hui Sia, Hoi Yin Loi, Tiong Cheng Yeo, Weiqin Lin   +8 more
doaj   +1 more source

Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background Outcomes data in patients with cardiac amyloidosis after implantable cardioverter‐defibrillator (ICD) implantation are limited. We compared outcomes of patients with ICDs implanted for cardiac amyloidosis versus nonischemic cardiomyopathies ...
Angela Y. Higgins, Amarnath R. Annapureddy, Yongfei Wang, Karl E. Minges, Rachel Lampert, Lynda E. Rosenfeld, Daniel L. Jacoby, Jeptha P. Curtis, Edward J. Miller, James V. Freeman   +9 more
doaj   +1 more source

Blood-based microRNA profiling in patients with cardiac amyloidosis. [PDF]

PLoS ONE, 2018
INTRODUCTION:Amyloidosis is caused by dysregulation of protein folding resulting in systemic or organ specific amyloid aggregation. When affecting the heart, amyloidosis can cause severe heart failure, which is associated with a high morbidity and ...
Anselm A Derda, Angelika Pfanne, Christian Bär, Katharina Schimmel, Peter J Kennel, Ke Xiao, P Christian Schulze, Johann Bauersachs, Thomas Thum   +8 more
doaj   +1 more source

Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis. [PDF]

ESC Heart Fail
Abstract Aims This study aimed to evaluate the change of the main electrocardiographic (ECG) characteristics and their prognostic role across the main subtypes of cardiac amyloidosis [light‐chain amyloidosis (AL) and hereditary (ATTRv) and wild‐type transthyretin amyloidosis (ATTRwt)].
Argirò A, Zampieri M, Mazzoni C, Fumagalli C, Baccini M, Mattei A, Cipriani A, De Michieli L, Porcari A, Sinagra G, Merlo M, Tini G, Musumeci B, Russo D, Vianello PF, Canepa M, Licordari R, di Bella G, Rapezzi C, Perfetto F, Cappelli F.   +20 more
europepmc   +2 more sources

High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy with Cardiovascular Deep Learning [PDF]

, 2021
Left ventricular hypertrophy (LVH) results from chronic remodeling caused by a broad range of systemic and cardiovascular disease including hypertension, aortic stenosis, hypertrophic cardiomyopathy, and cardiac amyloidosis. Early detection and characterization of LVH can significantly impact patient care but is limited by under-recognition of ...
arxiv   +1 more source

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2—Diagnostic Criteria and Appropriate Utilization [PDF]

, 2019
Cardiac amyloidosis is emerging as an underdiagnosed cause of heart failure and mortality. Growing literature suggests that a noninvasive diagnosis of cardiac amyloidosis is now feasible.
Ando, Y, Bokhari, S, Bourque, JM, Dispenzieri, A, Dorbala, S, Falk, RH, Ferrari, VA, Fontana, M, Gheysens, O, Gillmore, JD, Glaudemans, AWJM, Hanna, MA, Hazenberg, BPC, Kristen, AV, Kwong, RY, Maurer, MS, Merlini, G, Miller, EJ, Moon, JC, Murthy, VL, Quarta, CC, Rapezzi, C, Ruberg, FL, Shah, SJ, Slart, RHJA, Verberne, HJ   +25 more
core   +4 more sources

Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome [PDF]

, 2013
Background Cardiac amyloidosis is a fatal disease whose prognosis and treatment rely on identification of the amyloid type. In our aging population transthyretin amyloidosis (ATTRwt) is common and must be differentiated from other amyloid types.
Banypersad, SM, Dungu, J, Gibbs, SD, Gilbertson, JA, Gillmore, JD, Hawkins, PN, Lachmann, HJ, McCarthy, CA, Petrie, A, Pinney, JH, Rowczenio, D, Sattianayagam, P, Venner, CP, Wassef, N, Wechalekar, A, Whelan, CJ   +15 more
core   +1 more source

Transthyretin cardiac amyloidosis

Cardiovascular Research, 2022
AbstractTransthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have shifted ATTR-CA from a rare and untreatable disease to a relatively prevalent condition that clinicians should consider on a
Aldostefano Porcari, Marianna Fontana, Julian D Gillmore   +2 more
openaire   +4 more sources